HR Execs on the Move

AstraZeneca

www.astrazeneca.com

 
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.astrazeneca.com
  • 1800 Concord Pike P.O. Box 15437
    Wilmington, DE USA 19850
  • Phone: 302.886.3000

Executives

Name Title Contact Details
Jacqueline Vulpis
Network Supply Planner Profile
Simon Allison
Finance Director Profile
Nancy Tiran
Global Head of Commercial Procurement Profile
Callum Chapman
Head of Commercial Product Quality Profile
Danette Toole
Talent Acquisition Partner Profile

Similar Companies

R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers R1`s proven and scalable operating models seamlessly complement a healthcare organization`s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience.

Mitchell and Resnikoff

Mitchell & Resnikoff is a Elkins Park, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clearworth Systems

Clearworth Systems is a Rumson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioniche Pharma USA

Bioniche Pharma USA LLC is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.